ABSTRACT
Aims & Objectives: To study the effect of COVID 19 on different hematological services. Patients/Materials & Methods: This observational study included 18 patients evaluated from June 2020 till September 2020 belonging to various age groups with a WHO defined hematological disease with laboratory-confirmed and symptomatic COVID-19. The primary outcome was mortality and evaluation of COVID-19 severity in different hematological diseases assessed on day 14 and 28. Patient characteristics, type of disease, symptomatology, HRCT findings and baseline qCRP levels were recorded and the need for oxygenation or in vasiveventilation with administration of various drugs and convalescent plasma and its consecutive effect in delay or nonadministration of chemotherapyevaluated. Results: A total of 140 hematology patients were admitted of which 18 patients (12.85%) were COVID-19 positive. 10 cases (55.55%) were of B cell Acutelymphoblasticleukemia (B-ALL), 3(16.66%) of acutemyeloidleukemia (AML) and 1 (5.55%) each of acute promyelocytic leukemia (APL), T cell acute lymphoblastic leukemia (TALL), T-Lymphoblastic lymphoma (T-LBL), Hodgkins lymphomaandaplasticanaemia. Majority of patients had mild COVID-19 infection (72.22%, n = 13), 4 cases (22.22%) were severely affected and 1 moderately affected. There was delay in administration in chemotherapy in 14 cases(77.77%), while 3 patients continued to receive chemotherapy during the viralillness. Survival at day 14 and 28 in B-ALL was 100%, survival in AML on day 14 and day 28 was 66.6%, survivalin T-ALL on day 14 was 100% and 0% on day 28, survivalin APL and T-LBL on day 14 was0%, survivalin Hodgkinslymphomaandaplasticanemia on day 14 and day 28 was 100%. Discussion & Conclusion: The results indicate that 12.85% cases were COVID-19 positive. 72.22% had mild COVID-19 infection and 22.22% had severe COVID-19 infection. The most common affected was B-ALL (55.55%). In 77.77% cases there was delay in administration of chemotherapy.